Back to search

National and Kapodistrian University of Athens

Ανίχνευση μεταλλάξεων στο ογκοκατασταλτικό γονίδιο TP53 και ποσοτικός προσδιορισμός της p53 πρωτεΐνης σε ασθενείς με δρεπανοκυτταρικά σύνδρομα που λαμβάνουν υδροξυουρία για μακρό χρονικό διάστημα

Abstract

dc:description

The purpose of this study is the analysis of TP53 gene and the determination of p53 protein in patients with SCD, being under treatment with HU from 3-8 years. TP53 gene contributes to the reparation process of DNA as well as to apoptosis whereas its mutations consist one of the mayor and early events in the pathogenesis of malignant transformation. Its disorders are often accompanied by mutated protein production that is characterized by greater stability in relation to wild type protein. The identification of certain changes, occurring in the TP53 gene and the corresponding protein, could imply the possible mutagen or leukemogen action of HU. 51 patients with SCD are included in the study, who take HU since 1991 until today. Initially all 51 patients were studied following 0-62 months of treatment with median duration a 28,2-month period. 26 of them were re-examined during the term of 51-97 months of treatment with median duration an 68,1-month term. 10 of 51 patients were re-examined during the term of 31-43 months of treatment with median duration an 37,9-month term. The tracing of mutations in TP53 gene was based on the PCR- SSCP analysis. Following the extraction of RNA, and the production of cDNA, four DNA areas measuring a length of 257-302 Bp, in which exons 5-11 are included, were selectively enhanced with PCR. SSCP analysis followed, and the set off of single strand selected areas of DNA following the staining of gel with silver nitrate. The determination of p53 phosphoprotein in the serum of the patients was accomplished by means of the non-antagonistic Elisa, where the antigen was defined with the double antibody method. The SSCP analysis of TP53 in the 87 samples did not reveal disorders in the electrophoretic mobility, and consequently structural abnormalities of the selected single-strand regions. The quantitative determination of the p53 antigen in these patients with SCD and normal SSCP analysis of TP53, revealed antigen concentrations ranging within 1,5-20 pg/ml. On the contrary, the comparative quantitative determination of p53 patients with hematological malignancies of poor prognosis and pathological SSCP analysis of p53 gene, revealed p53 antigen concentrations ranging within 90-850 pg/ml. The non-identification of certain disorders of the TP53 gene and the p53 protein could characterize the term of 3-8 years of treatment with HU of the patients with SCD, as adequately safe as to its potentially mutagen or leukemogen action of HU.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2002

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Mougiou, Athina
  • Μούγιου, Αθηνά

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/20021

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Mougiou, Athina; Μούγιου, Αθηνά. Ανίχνευση μεταλλάξεων στο ογκοκατασταλτικό γονίδιο TP53 και ποσοτικός προσδιορισμός της p53 πρωτεΐνης σε ασθενείς με δρεπανοκυτταρικά σύνδρομα που λαμβάνουν υδροξυουρία για μακρό χρονικό διάστημα. National and Kapodistrian University of Athens, 2002. http://hdl.handle.net/10442/hedi/20021